Mirion Medical partners with The Foundation for the National Institutes of Health (FNIH) on Radiopharmaceutical Therapy Innovation Project
Announcing contributions of essential equipment and expertise to the Precision Dosimetry Imaging Biomarker (PDIB) Project to advance cancer care.
Mirion, through our family of medically focused brands, was recently named a partner on a new collaborative project aimed at enhancing radiopharmaceutical therapies, leading to improved survival rates and quality of life for those battling cancer.
The PDIB project, led by the FNIH Biomarkers Consortium, brings together a diverse array of government, industry, and academic organizations with the goal of developing more effective radiopharmaceutical therapies (RPTs). This initiative is closely aligned with the Mirion Medical mission, which is dedicated to driving the Science of Better. We are committed to enhancing the quality of cancer care, from the initial diagnosis through every stage of the patient journey.
What are Radiopharmaceutical Therapies (RPTs)?
RPTs represent significant potential in cancer care. This approach injects radiation directly into cancer cells, minimizing damage to healthy tissue and reducing side effects. Unlike traditional radiation therapy, which directs radiation beams to the tumor region, RPTs are highly specific and targeted.
While these new treatments have significant potential to improve the quality of life for patients, improvements to standards and methods are needed. Because current methods for measuring RPT radiation vary between treatment centers, it is difficult to optimize patient care, often leading to conservative treatment strategies that underdose patients and result in suboptimal outcomes. The FNIH cross-functional consortium brings together leaders to address these challenges in a collaborative and effective study.
Mirion’s Contributions to PDIB Project
Recognizing Capintec’s leadership in dose calibration and Sun Nuclear’s phantom capabilities, Mirion is proud to donate nuclear medicine imaging phantoms used to ensure the safety and effectiveness of radiopharmaceutical therapies. This equipment will play a crucial role in meeting the objectives of the PDIB project.
“This initiative is a big step toward advancements in personalized radiation therapy,” Mettler said. “This project is a perfect match for Mirion and our family of medical brands, allowing us to apply our expertise in nuclear medicine and personalized dosimetry to enhance care and support new developments in radiopharmaceutical therapies.”
Mirion will also collaborate with the project team, bringing valuable expertise in nuclear medicine and personalized dosimetry. Steve Mettler, president of Capintec, a Mirion Medical company, will serve as the Mirion representative on the PDIB project. Steve will apply his 30+ years of experience in technical, commercial, and management roles to help ensure the highest standards of precision and innovation.
Steve Mettler
President, Capintec
Mirion values partnerships that fundamentally change what’s possible in science, industry, and medicine. Our involvement in the PDIB project is a testament to the power of collaboration and the potential of advanced medical technologies and treatments to transform lives. Together with FNIH and the PDIB project’s other partners, we look forward to this opportunity to make a significant difference in the lives of those affected by cancer.
Learn more about Mirion’s Cancer Care solutions here, and see PDIB project details here.
